Topics

Governments must make tackling AMR worth pharmacy's while

09:36 EST 4 Dec 2019 | The Pharmaceutical Journal

Pharmaceutical companies won’t develop fast, cheap and effective diagnostic tools on their own — they need incentives to tackle antimicrobial resistance.

Original Article: Governments must make tackling AMR worth pharmacy's while

NEXT ARTICLE

More From BioPortfolio on "Governments must make tackling AMR worth pharmacy's while"

Quick Search